Anti-Mouse IFNß [Clone HDß-4A7] — Purified in vivo GOLD™ Functional Grade

In Vivo Applications of Clone HDß-4A7 in Mice

Clone HDß-4A7 is a monoclonal antibody specifically targeting mouse interferon-beta (IFN-β). Its primary in vivo application is the selective neutralization of murine IFN-β activity in experimental mouse models, allowing researchers to investigate the biological roles of this cytokine.

Key Uses in Mouse Studies

• Blockade of IFN-β Signaling: HDß-4A7 is administered to mice to systemically block IFN-β, thereby mimicking the phenotype of IFN-β-deficient (IFN-β−/−) mice. This enables the study of IFN-β’s contributions to immune responses, viral pathogenesis, and disease outcomes without the confounding effects of genetic knockout.
• Viral Infection Models: A notable application is in models of West Nile Virus (WNV) infection. Treatment with HDß-4A7 increases the lethality of WNV-infected mice, closely resembling the susceptibility observed in IFN-β−/− mice. This demonstrates the critical role of IFN-β in host defense against specific viruses.
• Mechanistic Studies: By selectively neutralizing IFN-β (without affecting other type I interferons like IFN-α or IFN-γ), HDß-4A7 allows researchers to dissect the unique functions of IFN-β in innate immunity, antiviral defense, and possibly autoimmunity.
• Comparative Studies: HDß-4A7 is sometimes used alongside other antibodies (e.g., MAR1-5A3, which blocks the IFN-α/β receptor) to compare the effects of IFN-β-specific versus pan-type I IFN blockade.

Technical Details

• Specificity: HDß-4A7 binds both recombinant and natural murine IFN-β, but not IFN-γ or several IFN-α subtypes, ensuring selective blockade.
• Pharmacokinetics: The antibody has a circulation half-life of approximately 14 days in mice, supporting sustained in vivo neutralization.
• Dosing: Optimal dosing should be determined empirically for each experimental context, as efficacy may vary with infection model, mouse strain, and experimental endpoint.

Summary Table: Common In Vivo Uses of HDß-4A7

Conclusion

Clone HDß-4A7 is a valuable tool for in vivo studies in mice, primarily used to selectively neutralize IFN-β and investigate its specific roles in immunity, viral pathogenesis, and disease. Its applications are most prominent in viral infection models, where it has been shown to critically increase susceptibility to pathogens like West Nile Virus, mirroring the phenotype of IFN-β−/− mice. This antibody enables precise, cytokine-specific interrogation of the immune system in vivo.

Based on the available information, HDß-4A7 is a monoclonal antibody that specifically targets mouse interferon-beta (IFN-β). While the search results mention this antibody, they do not provide detailed information about other commonly used antibodies or proteins that are frequently paired with HDß-4A7 in published research.

HDß-4A7 is characterized as a mouse anti-mouse IFN-β antibody that recognizes an epitope on mouse IFN-β and binds specifically to murine IFN-β without binding to murine IFN-γ or several different IFN-α species. The antibody has demonstrated functional activity in both in vitro and in vivo studies, including its ability to inhibit IFN-β-induced STAT1 phosphorylation and block IFN-β induction of MHC-I expression.

However, the search results explicitly state that based on the available information, specific details about other commonly used antibodies or proteins used alongside HDß-4A7 in the literature cannot be determined. To obtain this information, you would need to conduct a more comprehensive literature review of studies utilizing HDß-4A7, particularly focusing on research involving interferon signaling pathways, viral infection models, and immune response studies where this antibody has been employed.

Key Findings from Clone HDß-4A7 (Anti-Mouse IFN-β) Citations in Scientific Literature

Specificity and Binding Characteristics

• Clone HDß-4A7 (Mouse Anti-Mouse IFN-β) is a monoclonal antibody that binds specifically to murine interferon-beta (IFN-β) and does not cross-react with murine IFN-γ or several IFN-α subtypes (α-1, a-4, a-5, a-13).
• The antibody recognizes both recombinant and natural forms of mouse IFN-β, and its epitope is distinct from those recognized by other anti-IFN-β antibodies.
• Distribution: IFN-β is expressed primarily on fibroblasts and epithelial cells, and is a key mediator in the innate immune response, particularly during early viral or bacterial infections.

Functional In Vitro Activities

• Inhibition of Signal Transduction: HDß-4A7 inhibits IFN-β-induced STAT1 phosphorylation in cell lines, with a level of inhibition comparable to that achieved by anti-IFNAR1 monoclonal antibodies (e.g., MAR1-5A3).
• Blockade of MHC-I Induction: The antibody blocks IFN-β-induced upregulation of MHC class I (H2-Kb) molecules in L929 and fibrosarcoma cell lines.
• Neutralization of Antiviral Activity: HDß-4A7 neutralizes the antiviral activity of IFN-β in vitro, as demonstrated by increased susceptibility of L929 cells to vesicular stomatitis virus (VSV) infection when IFN-β is neutralized.

In Vivo Activities and Applications

• Blood Half-Life: The antibody circulates in vivo with an estimated half-life of approximately 14 days.
• Pathogen Susceptibility: Administration of HDß-4A7 in mice blocks endogenous IFN-β activity, leading to increased lethality in West Nile virus (WNV) infection, mirroring the susceptibility of IFN-β knockout mice.
• Therapeutic Targeting: IFN-β is a therapeutic target in multiple sclerosis, highlighting the relevance of tools like HDß-4A7 for studying IFN-β biology and potential therapeutic interventions.

Manufacturing and Quality

• Production: HDß-4A7 is produced in animal-free facilities using in vitro cell culture techniques, ensuring low levels of endotoxins and protein aggregates.
• Purification: The antibody is purified via multi-step affinity chromatography (Protein A or G), further ensuring high purity and low immunogenicity for in vivo use.

Summary Table of Key Features

Citation and Further Reading

• Primary citation: The antibody is referenced in the context of studies on IFN-β biology, with a specific citation to Oldstone et al. (2017) in PNAS (PubMed ID 3443708–3713).
• Applications: Suitable for Western blot (WB), blocking (B), and functional assays (FA) in both in vitro and in vivo settings.
• Availability: Distributed by Leinco Technologies Inc. and Fisher Scientific.

In summary, clone HDß-4A7 is a well-characterized tool for specifically blocking and studying murine IFN-β, with demonstrated efficacy in both cell-based assays and animal models of viral infection, and is notable for its high specificity, functional potency, and rigorous production standards.

No published dosing regimens for clone HDß-4A7 in mouse models are currently available in peer-reviewed literature or professional antibody dosing databases. Existing antibody dosing guides and research articles do not list clone HDß-4A7 among antibodies with established in vivo protocols for mice.

• The most relevant search result explicitly states: “No published dosing regimens for the antibody clone HDß-4A7 in mouse models…”.
• Dosing guides for other IFN-beta antibodies (including different clones for type I interferons) are typically provided with species, dose range, route, and schedule information, but these cannot be directly extrapolated to HDß-4A7 without experimental validation or manufacturer recommendations.

For alternative interpretations (such as Huntington’s disease mouse model dosing regimens), the identified resources do not mention HDß-4A7 in connection with HD mouse models.

• If HDß-4A7 is a research or newly developed clone, it may lack published characterization regarding pharmacokinetics, optimal dosing, or application protocol.

In summary:

• No published or standardized dosing regimens for HDß-4A7 across mouse models are available.
• For experimental planning, researchers should consult the antibody supplier for specific recommendations, or design pilot titration studies based on protocols established for related antibody clones.
• If more information is required, searching recent conference abstracts, preprints, or directly contacting manufacturers may be necessary.

If you need dosing guidelines for similar antibodies (e.g., IFN-beta or IFNAR1 targeting clones), protocols typically range from 0.2 mg to 2 mg per mouse by intraperitoneal injection, with schedules adapted to experimental contexts. This should only be considered after confirming biological and technical equivalence.